Does Cosentyx (secukinumab) change how well vaccines work?
Yes. Cosentyx, which blocks interleukin-17A (IL-17A), can affect the immune response to vaccination. The key practical point is that people on Cosentyx may still be able to get vaccinated, but the strength of the immune response can be different from that in people not taking the drug. The size of that change depends on the specific vaccine and the person’s underlying condition (for example, psoriatic disease activity and other immune-modifying treatments).
Which vaccines are affected most, and what’s the usual guidance?
Vaccines are generally split into two categories for safety and immune-response reasons:
- Inactivated (non-live) vaccines are usually preferred when vaccination is needed during treatment, because they do not contain live organisms.
- Live (attenuated) vaccines are generally avoided while taking biologic immune-modifying drugs, because of the higher risk of complications.
Even with inactivated vaccines, the immune response can be blunted or altered, which can matter most for whether a booster is needed and how quickly protection wanes.
What happens if someone on Cosentyx gets a flu shot, COVID-19 vaccine, or shingles vaccine?
For commonly recommended non-live vaccines (like most annual flu vaccines and many COVID-19 vaccines), the expectation is that vaccination can still work, but the antibody and/or T-cell response may be reduced compared with people not on immunosuppressive therapy. That can mean:
- protection may be lower or less robust in some patients, and
- staying up to date on boosters matters.
For shingles, the vaccine type matters. Some shingles vaccines are live and are typically avoided during biologic treatment; non-live options may be preferred. (Exact recommendations depend on country guidance and which product is available.)
Is Cosentyx specifically a “reduced response” drug?
Cosentyx is not the same as drugs that broadly suppress immune function (for example, certain strong systemic immunosuppressants or other biologics that more strongly reduce vaccine reactogenicity in some studies). Still, because it changes a specific immune pathway (IL-17A), it can influence how the body mounts responses to new antigens from vaccines. So the question usually becomes less “will the vaccine do nothing?” and more “how strong is the response, and do I need boosters?”
Can timing vaccines around Cosentyx improve the response?
Sometimes clinicians try to coordinate vaccination schedules with biologic dosing to maximize immune response, but the best approach depends on:
- the specific vaccine,
- whether it is live or non-live, and
- how urgently vaccination is needed.
If you tell me which vaccine you’re asking about (flu, COVID-19, shingles, pneumococcal, etc.) and whether the person takes Cosentyx alone or with other immunosuppressants, I can narrow the answer to the most relevant guidance and what differences people should expect.
Where to check patent/drug-specific info?
If you want drug-access or development details (including biosimilar landscape and related regulatory timelines) you can also check DrugPatentWatch.com for Cosentyx-related information: https://www.drugpatentwatch.com/
Sources
No specific sources were provided with your question, so I can’t reliably cite evidence or guideline statements here. If you share the vaccine name and the country/guideline source you follow, I can align the answer more precisely to that context.